Corline Biomedical AB (STO:CLBIO)
Sweden
· Delayed Price · Currency is SEK 15.65
-0.25 (-1.57%)
Mar 9, 2026, 5:29 PM CET
Corline Biomedical AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 | Upgrade
|
| Cash & Short-Term Investments | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 | Upgrade
|
| Cash Growth | 16.35% | 3.86% | -35.09% | -37.05% | 363.07% | Upgrade
|
| Accounts Receivable | 1.6 | 1 | 2.93 | 1.66 | 2.3 | Upgrade
|
| Other Receivables | 0.71 | 1.63 | 2.29 | 6.82 | 0.47 | Upgrade
|
| Receivables | 2.31 | 2.63 | 5.22 | 8.47 | 2.77 | Upgrade
|
| Prepaid Expenses | 1.12 | 0.75 | 1.57 | 1.31 | 0.42 | Upgrade
|
| Total Current Assets | 23.98 | 21.04 | 23.8 | 36 | 44.82 | Upgrade
|
| Property, Plant & Equipment | 0.16 | 0.22 | 0.31 | 0.28 | 0.18 | Upgrade
|
| Long-Term Investments | - | 0 | 0 | 0 | 0 | Upgrade
|
| Long-Term Deferred Charges | 74.43 | 73.5 | 75.99 | 65.5 | 56.66 | Upgrade
|
| Total Assets | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 | Upgrade
|
| Accounts Payable | 0.93 | 3.09 | 1.97 | 4.34 | 1.96 | Upgrade
|
| Accrued Expenses | 3.18 | 2.85 | 3.53 | 2.45 | 4.56 | Upgrade
|
| Other Current Liabilities | 0.71 | 1.91 | 1.29 | 0.4 | 2.91 | Upgrade
|
| Total Current Liabilities | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 | Upgrade
|
| Total Liabilities | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 | Upgrade
|
| Common Stock | 3.2 | 3.06 | 2.69 | 2.69 | 2.69 | Upgrade
|
| Additional Paid-In Capital | 192.81 | 171.39 | 155.19 | 155.19 | 155.19 | Upgrade
|
| Retained Earnings | -102.25 | 37.39 | 61.27 | 54.92 | 36.83 | Upgrade
|
| Comprehensive Income & Other | - | -124.92 | -125.83 | -118.21 | -102.47 | Upgrade
|
| Shareholders' Equity | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 | Upgrade
|
| Total Liabilities & Equity | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 | Upgrade
|
| Net Cash (Debt) | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 | Upgrade
|
| Net Cash Growth | 16.35% | 3.86% | -35.09% | -37.05% | 363.07% | Upgrade
|
| Net Cash Per Share | 0.83 | 0.81 | 0.79 | 1.19 | 2.04 | Upgrade
|
| Filing Date Shares Outstanding | 25.61 | 24.49 | 21.49 | 21.49 | 21.49 | Upgrade
|
| Total Common Shares Outstanding | 25.61 | 24.49 | 21.49 | 21.49 | 21.49 | Upgrade
|
| Working Capital | 19.16 | 13.2 | 17.01 | 28.8 | 35.39 | Upgrade
|
| Book Value Per Share | 3.66 | 3.55 | 4.34 | 4.40 | 4.29 | Upgrade
|
| Tangible Book Value | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 | Upgrade
|
| Tangible Book Value Per Share | 3.66 | 3.55 | 4.34 | 4.40 | 4.29 | Upgrade
|
| Machinery | - | 1.27 | 1.27 | 1.14 | 0.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.